CTx1000 designed to clear pathological TDP-43 protein, a central driver of ALS SYDNEY, March 24, 2...
* Recruitment successfully completed in Dimerix' ACTION3 Phase 3 clinical trial[1], which has rec...
SYDNEY, Sept. 11, 2025 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage Australian biotech, develop...
* Stephen Doyle has more than 24 years of experience in the global pharmaceutical industry, inclu...
SYDNEY, May 20, 2024 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage biotech developing novel immu...
SYDNEY, Nov. 13, 2023 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage Australian biotech, is pleas...
SYDNEY, Aug. 9, 2023 /PRNewswire/ -- Race Oncology Limited ("Race") is pleased to provide a strateg...
* HaemaLogiX and Peter MacCallum Cancer Centre have entered a collaboration agreement to develop ...
* Race Oncology executes agreement with leading global contract development and manufacturing org...
* Race Oncology executes agreement with leading global contract development and manufacturing org...
* Race executes worldwide license agreement with City of Hope, one of the largest cancer research...
* Race executes worldwide license agreement with City of Hope, one of the largest cancer research...
* Significant improvement in Overall Response Rate (83%) compared with matched case control group...
* INOVIQ's SubB2M/CA15-3 breast cancer test detects all-stages of breast cancer with excellent ac...
BRISBANE, Australia, May 31, 2023 /PRNewswire/ -- QBiotics Group Limited ( QBiotics), a clinical sta...
SYDNEY, March 28, 2023 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage biotech company developing ...
MELBOURNE, Australia, Nov. 15, 2022 /PRNewswire/ -- Australian mid-clinical stage antiviral drug de...
* Investigational new drug (IND) approval received by QBiotics, to initiate a Phase II clinical t...
* Dr. Geoff Nichol, M.B., Ch.B., M.B.A., joins HaemaLogiX's Board of Directors as Non-Executive D...
* New Board appointment deepens and consolidates Servatus' extensive commercial and scientific ex...